Novartis' Kelly Lindert Joins Tokai
This article was originally published in Scrip
Executive Summary
Tokai Pharmaceuticals Inc., a company focused on prostate cancer and other hormonal diseases, has appointed Kelly A. Lindert executive vice president and head of development. Lindert joins the company from Novartis AG where she spent eight years in various roles, most recently as global head of development for the company's influenza vaccines program.